BIOCYTOGEN PHARMA. H YC1 (I54) — Net Asset Quality Index
BIOCYTOGEN PHARMA. H YC1 (I54) has a Net Asset Quality Index of 58.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €3.72 Billion minus total liabilities of €1.54 Billion yields net assets of €2.18 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read BIOCYTOGEN PHARMA. H YC1 total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
BIOCYTOGEN PHARMA. H YC1 Net Asset Quality Index Over Time (2021–2025)
This chart shows how BIOCYTOGEN PHARMA. H YC1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 58.5%, representing net assets of €2.18 Billion against total assets of €3.72 Billion EUR. For live market cap and overall valuation, see I54 market cap.
Annual Net Asset Quality Index for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See I54 net asset value for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 58.5% | €2.18 Billion | €3.72 Billion | €1.54 Billion | ▲ +23.8 pp |
| 2024 | 34.7% | €838.60 Million | €2.42 Billion | €1.58 Billion | ▲ +2.4 pp |
| 2023 | 32.3% | €790.44 Million | €2.45 Billion | €1.66 Billion | ▼ -8.8 pp |
| 2022 | 41.1% | €1.15 Billion | €2.80 Billion | €1.65 Billion | ▼ -13.3 pp |
| 2021 | 54.4% | €1.25 Billion | €2.30 Billion | €1.05 Billion | — |